Pittsburgh, PANCT07198113Now EnrollingIRB Ready

Ulcerative Colitis, Pediatric Clinical Trial in Pittsburgh, PA

Access cutting-edge ulcerative colitis, pediatric treatment through this clinical trial at a research site in Pittsburgh. Study-provided care at no cost to qualified participants.

Sponsored by University of North Carolina, Chapel Hill

Quick Self-Assessment

See if you qualify for this Pittsburgh location

Preparing your pre-screening questions…

Expert Care in Pittsburgh

Access ulcerative colitis, pediatric specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related ulcerative colitis, pediatric treatment provided free

Apply for This Pittsburgh Location

Check if you qualify for this ulcerative colitis, pediatric clinical trial in Pittsburgh, PA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Pittsburgh

    Convenient for PA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Pittsburgh site if eligible
  4. 4Begin participation

About This Ulcerative Colitis, Pediatric Study in Pittsburgh

The purpose of the study is to compare the clinical effectiveness and safety of newer inflammatory bowel disease (IBD) medications in anti-tumor necrosis factor (TNF) refractory patients with pediatric IBD (PIBD). Refractory means that there was no clinical response to anti-tumor necrosis factor (TNF) drugs or that the if there was a response, it is no longer present. The main question this study aims to answer is: Are the newer medications used to treat IBD just as safe and effective for treating IBD in children. Participants will already be taking these newer medications as assigned by their regular health care provider.Participants' care will be managed by their regular healthcare provider as part of usual (standard) care for those with PIBD. While taking these medications, participants will be asked to answer questions about their symptoms and health periodically over the course of the study.

Sponsor: University of North Carolina, Chapel Hill

Who Can Participate

Inclusion Criteria

Age \< 18 years at study enrollment
Diagnosis of CD, UC, or IBD-U by standard diagnostic criteria
Prior non-response or loss of response to one or more anti-TNF agents
Planning to initiate treatment with any of the following comparator agents: vedolizumab (α4β7 integrin antibody), ustekinumab (anti-IL-12/23 antibody), risankizumab, guselkumab, or mirikizumab, (IL-23 inhibitors), tofacitinib (JAK inhibitor), and upadacitinib (JAK inhibitor). Biosimilars or generic medications for any of the above will also be allowed and handled/analyzed in an identical manner to originators.
Ability to provide child assent, if required per regulatory or local institutional guidelines, and parental informed consent in English or Spanish

Exclusion Criteria

Plans to change care to a different center within 1 year
Prior use of a comparator agent (i.e., only patients starting their first comparator medication as monotherapy following anti-TNF will be eligible)
Contraindication to any of the treatments under investigation
Patients with UC or IBD-U who have undergone colectomy
Patients with current ostomy

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Pittsburgh?

Yes, this clinical trial (NCT07198113) has an active research site in Pittsburgh, PA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Ulcerative Colitis, Pediatric Treatment Options in Pittsburgh, PA

If you're searching for ulcerative colitis, pediatric treatment options in Pittsburgh, PA, this clinical trial (NCT07198113) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Pittsburgh research site is actively enrolling participants for this clinical trial. You'll receive care from experienced ulcerative colitis, pediatric specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all ulcerative colitis, pediatric clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Embolism Trials in Pittsburgh, PA

See all pulmonary embolism clinical trials recruiting in Pittsburgh — not just this study.

Browse Pulmonary Embolism Trials in Pittsburgh

Ready to Join in Pittsburgh?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Pittsburgh, PA